Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Extra Space Storage, Inc. (EXR) vs Novo Nordisk A/S (NVO) Price & Performance

Extra Space Storage, Inc.Trade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Extra Space Storage, Inc. vs Novo Nordisk A/S — how do they compare? Extra Space Storage, Inc. trades at $147.58 (market cap $30.56B), while Novo Nordisk A/S trades at $51.62 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 7.3× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.48%). Which is the better fit depends on your goals.

EXRNVO
Market Cap
$30.56B$222.24B
Sector
Real EstateHealth
52-Week High
$152.75$71.70
52-Week Low
$126.67$35.29
Enterprise Value
$44.36B$241.20B
Dividend Yield
4.48%3.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Extra Space Storage, Inc.

Extra Space Storage (EXR) trades at $145.50, showing modest daily gains of 0.12%. The stock exhibits neutral technical signals with support around $145 and resistance near $146. Fundamentally, the company maintains strong profitability with a 70.63% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights steady expansion and a new $550 million debt issuance at favorable rates, while analyst coverage shows a mixed consensus leaning toward Hold positions.

The outlook for EXR balances steady operational performance against valuation concerns. Investment opportunities include resilient self-storage demand, consistent dividend payments ($1.62 quarterly), and strategic acquisitions. Key risks involve elevated debt levels, new market supply pressures, and expense growth outpacing revenue. With a consensus price target of $155.88 suggesting 7% upside, the stock presents moderate growth potential tempered by sector headwinds.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.

The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Extra Space Storage, Inc.

Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.

Read more on EXR

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO